- Trials with a EudraCT protocol (4,216)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (372)
4,216 result(s) found for: Imaging.
Displaying page 9 of 211.
EudraCT Number: 2017-001471-23 | Sponsor Protocol Number: UZBRU_VHH2_1 | Start Date*: 2019-02-06 |
Sponsor Name:UZ Brussel | ||
Full Title: Phase I/IIa study to evaluate the safety, biodistribution, radiation dosimetry and tumor imaging potential of 68GaNOTA-Anti-MMR-VHH2, a new radiopharmaceutical for in vivo imaging of Tumour-Associa... | ||
Medical condition: Tumour associated macrophages found in tumour lesions of two cancer types: breast cancer or melanoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2016-003622-16 | Sponsor Protocol Number: T214/2016 | Start Date*: 2017-09-19 |
Sponsor Name:Turku University Hospital | ||
Full Title: Targeting SPMS: Effect of teriflunomide treatment on microglial activation in an MS patient cohort at risk of progression. A [11C]PK11195 Brain PET study. | ||
Medical condition: Multiple sclerosis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FI (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-005214-18 | Sponsor Protocol Number: T705-COVID-GCRI-Protocol-B | Start Date*: 2021-02-01 |
Sponsor Name:Vilnius University Hospital Santaros klinikos | ||
Full Title: An Investigation of the Efficacy and Safety of Favipiravir in COVID-19 Patients without Pneumonia − An open-label randomized controlled study | ||
Medical condition: COVID-19 Patients without Pneumonia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: LT (Prohibited by CA) | ||
Trial results: (No results available) |
EudraCT Number: 2006-003012-21 | Sponsor Protocol Number: AI-700-34 | Start Date*: 2006-12-28 | |||||||||||
Sponsor Name:Acusphere, Inc. | |||||||||||||
Full Title: A Phase 3, International, Exploratory, Open-Label, Multicenter, Dual-Injection, Echocardiographic Imaging Settings and Safety Study of AI-700 in Normal Volunteers and Stable Cardiac Patients (Acqui... | |||||||||||||
Medical condition: AI-700 is an intravenous (IV) ultrasound contrast agent designed for echocardiographic imaging for myocardial defect detection. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-004170-25 | Sponsor Protocol Number: MH-110 | Start Date*: Information not available in EudraCT |
Sponsor Name:Bracco Imaging S.p.A. | ||
Full Title: A PHASE III, MULTI-CENTER, OPEN-LABEL STUDY TO EVALUATE SAFETY AND EFFICACY OF MULTIHANCE® AT THE DOSE OF 0.10 mmol/kg IN MAGNETIC RESONANCE IMAGING OF THE CENTRAL NERVOUS SYSTEM IN PEDIATRIC PA... | ||
Medical condition: imaging diagnosis of highly suspected or known brain and/or spine disease, which are known to impair the Blood Brain Barrier Function | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Completed) BE (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-004746-33 | Sponsor Protocol Number: 310123 | Start Date*: 2008-09-17 | |||||||||||
Sponsor Name:Bayer HealthCare Pharmaceuticals INC | |||||||||||||
Full Title: A multicenter, randomized, double-blind, crossover, phase 3 study to determine the safety and efficacy of gadobutrol 1.0 molar (Gadovist®) in patients referred for contrast-enhanced MRI of the cent... | |||||||||||||
Medical condition: Male and female patients of any ethnic group who are referred for a contrast-enhanced MRI of the CNS based on current clinical symptoms or results of a previous imaging procedure. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001502-15 | Sponsor Protocol Number: 2016-01382 | Start Date*: 2017-12-13 | |||||||||||
Sponsor Name:Insel Gruppe AG - Inselspital | |||||||||||||
Full Title: Effects of the PCSK9 Antibody AliroCuMab on Coronary Atherosclerosis in PatieNts with Acute Myocardial Infarction. A Serial, Multivessel, Intravascular Ultrasound, Near-Infrared Spectroscopy And Op... | |||||||||||||
Medical condition: Patients presenting with acute myocardial infarction (non-ST-elevation myocardial infarction or acute ST-elevation myocardial infarction) and with elevated cholesterol levels. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000934-53 | Sponsor Protocol Number: 104-13-302 | Start Date*: 2014-11-11 | |||||||||||
Sponsor Name:Celsion Corporation | |||||||||||||
Full Title: A Phase III, Randomized, Double Blind, Dummy-Controlled Study of ThermoDox® (Lyso-Thermosensitive Liposomal Doxorubicin-LTLD) in Hepatocellular Carcinoma (HCC) using standardized Radiofrequency Abl... | |||||||||||||
Medical condition: Hepatocellular Carcinoma (HCC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003382-18 | Sponsor Protocol Number: BED-PSMA-302 | Start Date*: 2020-05-25 | |||||||||||
Sponsor Name:Blue Earth Diagnostics Ireland Ltd. | |||||||||||||
Full Title: A prospective, Phase 3, multi-center, single-arm, imaging study investigating the safety and diagnostic performance of rhPSMA-7.3 (18F) PET ligand in men with suspected prostate cancer recurrence b... | |||||||||||||
Medical condition: Prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: FI (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000304-96 | Sponsor Protocol Number: NL47648.029.14 | Start Date*: 2015-01-15 | |||||||||||
Sponsor Name:VU University Medical Center (VUmc) | |||||||||||||
Full Title: Sentinel lymph node identification in colon cancer using a radioactive and fluorescent tracer | |||||||||||||
Medical condition: Colon Carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-024044-15 | Sponsor Protocol Number: BMS747158-301 | Start Date*: 2011-06-08 | |||||||||||
Sponsor Name:Lantheus Medical Imaging, Inc. | |||||||||||||
Full Title: A Phase 3, Open-Label, Multicenter Study for the Assessment of Myocardial Perfusion using Positron Emission Tomography (PET) Imaging of Flurpiridaz F 18 Injection in Patients with Suspected or Know... | |||||||||||||
Medical condition: Assessment of myocardial perfusion using Positron Emission Tomography (PET) Imaging of Flurpiridaz F 18 Injection in patients with suspected or known coronary artery disease. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-002692-18 | Sponsor Protocol Number: 20150616 | Start Date*: 2015-10-29 | |||||||||||
Sponsor Name:European Commission | |||||||||||||
Full Title: The physiology of glucagon-like peptide-1 receptor expression in patients with endogenous hyperinsulinism: correlation with histopathology | |||||||||||||
Medical condition: Congenital hyperinsulinism | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Not Authorised) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-005278-40 | Sponsor Protocol Number: ABR-55752 | Start Date*: 2016-11-29 | |||||||||||
Sponsor Name:Radboudumc | |||||||||||||
Full Title: Molecular imaging before and during (chemo-) radiotherapy in patients with locally advanced Head and Neck, thoracic and pelvic tumors: prognostic and predictive value of 18F-fluoroazomycin arabinos... | |||||||||||||
Medical condition: Head and neck squamous cell carcinoma (HNSCC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002643-28 | Sponsor Protocol Number: CA209-8JD | Start Date*: 2019-02-25 | |||||||||||
Sponsor Name:Amsterdam UMC, location VUmc | |||||||||||||
Full Title: Safety and tolerability of neoadjuvant nivolumab for locally advanced resectable oral cancer, combined with [18F]BMS-986192 / [18F]-FDG PET imaging and immunomonitoring for response prediction. | |||||||||||||
Medical condition: Stage III/IV resectable oral squamous cell carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-000998-31 | Sponsor Protocol Number: APHP220267 | Start Date*: 2023-03-10 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: Study of the benefit of lenvatinib treatment in waiting list of liver transplantation after TACE failure in patients with hepatocellular carcinoma (HCC) : Ta-Len-Tra. | |||||||||||||
Medical condition: Patients with a non resectable HCC registered on national waiting list for LT with no complete response to TACE as a bridging loco-regional treatment. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002720-12 | Sponsor Protocol Number: GDX-44-016 | Start Date*: 2023-03-20 | |||||||||||
Sponsor Name:Guerbet | |||||||||||||
Full Title: Performance of Elucirem® (gadopiclenol) in Dynamic Susceptibility Contrast Magnetic Resonance Imaging (DSC-MRI) perfusion of brain gliomas | |||||||||||||
Medical condition: Naive or recurrent primary glial tumor | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000580-90 | Sponsor Protocol Number: ASSTBS-ONCO-ACACIA-18 | Start Date*: 2018-06-20 | |||||||||||
Sponsor Name:AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA | |||||||||||||
Full Title: Multicenter randomized open-label phase III trial of Adjuvant Chemotherapy vs. observation or mitotane after primary surgical resection of localized | |||||||||||||
Medical condition: localized Adrenocortical CarcInomA with high risk of recurrence | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-002678-29 | Sponsor Protocol Number: BMS747158-302 | Start Date*: 2013-02-21 | |||||||||||
Sponsor Name:Lantheus Medical Imaging, Inc. | |||||||||||||
Full Title: A Phase 3, Open-Label, Multicenter Study for the Assessment of Myocardial Perfusion using Positron Emission Tomography (PET) Imaging of Flurpiridaz F 18 Injection in Patients with Suspected or Know... | |||||||||||||
Medical condition: Assessment of myocardial perfusion using Positron Emission Tomography (PET) Imaging of Flurpiridaz F 18 Injection in patients with suspected or known coronary artery disease. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000986-17 | Sponsor Protocol Number: ALZ-801-201ADBM | Start Date*: 2020-09-11 |
Sponsor Name:Alzheon Inc. | ||
Full Title: A Phase 2, Single Arm, Study of the Biomarker Effects of ALZ-801 in Subjects with Early Alzheimer’s Disease Who Are Carriers of the ε4 Variant of the Apolipoprotein E Gene (APOE4/4 or APOE3/4) | ||
Medical condition: Subjects with a clinical diagnosis of Alzheimer's disease who are APOE 4 carriers (APOE4/4, APOE3/4) and at the Early stage of disease, ages 50-80 years | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Trial now transitioned) NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2015-004567-36 | Sponsor Protocol Number: MK-3475-240 | Start Date*: 2016-05-13 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase III Study of Pembrolizumab (MK-3475) vs. Best Supportive Care as Second-Line Therapy in Subjects with Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-240) | |||||||||||||
Medical condition: Hepatocellular Carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) DE (Completed) DK (Completed) HU (Completed) FR (Completed) GB (GB - no longer in EU/EEA) PL (Completed) BE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
